ResearcherThe University of OsakaActive in the last 2 years

Akikazu Harada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8123-652X; OpenAlex author ID A5063001072. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Newly developed humanized anti-CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1-CKAP4 signaling. Co-author DOI 10.1111/cas.16278 ↗
Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion. Co-author DOI 10.7554/elife.66721 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Akira Kikuchi · 2 shared papers, 2021–2024 · strength 0.43
- Paper Newly developed humanized anti-CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1-CKAP4 signaling. DOI 10.1111/cas.16278 ↗
- Paper Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion. DOI 10.7554/elife.66721 ↗
Ryota Sada · 1 shared paper, 2024 · strength 0.28
- Paper Newly developed humanized anti-CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1-CKAP4 signaling. DOI 10.1111/cas.16278 ↗
Hidetoshi Eguchi · 1 shared paper, 2021 · strength 0.15
- Paper Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion. DOI 10.7554/elife.66721 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.